drugset / Trial / NCT00300807
Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection
RandomizedDouble-blindTreatment
Summary
1. Evaluate the safety, tolerability, and virologic activity of escalating single (and multiple) doses of XTL6865, a mixture (1:1) of two human monoclonal antibodies (HCV-AbXTL68 and HCV-AbXTL65), in patients with chronic hepatitis C virus infection. 2. Assess the pharmacokinetics of XTL6865 in the presence and absence of viral infection.
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XTL6865 | Monoclonal antibody | 5 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 20 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 75 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 250 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 600 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 1200 mg | — |
| Subject | XTL6865 | Monoclonal antibody | 2400 mg | — |